Please login (Members) to view content or (Nonmembers) this article.
(1 vote)
Oncology Update
Oncology Update
ONF 2011, 38(6), 739-740 DOI: 10.1188/11.ONF.739-740
Crizotinib (Xalkori®), an oral anaplastic lymphoma kinase (ALK) inhibitor, has received U.S. Food and Drug Administration (FDA) approval for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that has tested positive for ALK gene abnormalities.
Members Only
Access to this article is restricted. Please login to view the full article.